Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells

Front Immunol. 2023 Aug 10:14:1229341. doi: 10.3389/fimmu.2023.1229341. eCollection 2023.

Abstract

NK cells represent important effectors that play a major role in innate defences against pathogens and display potent cytolytic activity against tumor cells. An array of surface receptors finely regulate their function and inhibitory checkpoints, such as PD-1, can dampen the immune response inducing an immunosuppressive state. Indeed, PD-1 expression in human NK cells correlated with impaired effector function and tumor immune evasion. Importantly, blockade of the PD-1/PD-L1 axis has been shown to reverse NK cell exhaustion and increase their cytotoxicity. Recently, soluble counterparts of checkpoint receptors, such as soluble PD-1 (sPD-1), are rising high interest due to their biological activity and ability to modulate immune responses. It has been widely demonstrated that sPD-1 can modulate T cell effector functions and tumor growth. Tumor-infiltrating T cells are considered the main source of circulating sPD-1. In addition, recently, also stimulated macrophages have been demonstrated to release sPD-1. However, no data are present on the role of sPD-1 in the context of other innate immune cell subsets and therefore this study is aimed to unveil the effect of sPD-1 on human NK cell function. We produced the recombinant sPD-1 protein and demonstrated that it binds PD-L1 and that its presence results in increased NK cell cytotoxicity. Notably, we also identified a pathway regulating endogenous sPD-1 synthesis and release in human NK cells. Secreted endogenous sPD-1, retained its biological function and could modulate NK cell effector function. Overall, these data reveal a pivotal role of sPD-1 in regulating NK-mediated innate immune responses.

Keywords: NK cells; cancer; immunotherapy; neuroblastoma; soluble PD-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen*
  • Biological Transport
  • Cell Death
  • Humans
  • Killer Cells, Natural
  • Programmed Cell Death 1 Receptor*

Substances

  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor

Grants and funding

This work was supported by Associazione Italiana per la ricerca sul Cancro (project no. 5x1000 2018 Id 21147 to LM, project no. IG 2017 Id 19920 to LM, IG2022 Id.27065 to PV) and by Current Research found 5x1000 project no. 202305_IMMUNO_MARIOTTI to FRM. FRM was supported by Fondazione Umberto Veronesi. NL is supported by the i-CARE fellowship awarded by AIRC and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant agreement No. 800924NL). This work was supported also by the Italian Ministry of Health with “Current research funds”.